Skip to main content

Table 1 Baseline demographics

From: Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study

Variable

Level

Overall

Eptinezumab

Erenumab

Fremanezumab

Galcanezumab

OnabotulinumtoxinA

N = 66,576

n = 1,074

n = 17,617

n = 6,299

n = 17,221

n = 24,365

Age, median (Q1, Q3)

 

46 (36, 54)

46 (38, 55)

45 (35, 53)

46 (36, 54)

45 (36, 53)

47 (37, 55)

Sex, n (%)

Female

58,983 (88.59)

929 (86.50)

15,402 (87.43)

5,545 (88.03)

15,101 (87.69)

22,006 (90.32)

Male

7,593 (11.41)

145 (13.50)

2,215 (12.57)

754 (11.97)

2,120 (12.31)

2,359 (9.68)

Payer type, n (%)

Other

8,018 (12.04)

125 (11.64)

1,884 (10.69)

1,046 (16.61)

2,010 (11.67)

2,953 (12.12)

HMO

10,041 (15.08)

180 (16.76)

2,457 (13.95)

1,026 (16.29)

2,534 (14.71)

3,844 (15.78)

PPO

48,517 (72.87)

769 (71.60)

13,276 (75.36)

4,227 (67.11)

12,677 (73.61)

17,568 (72.10)

Migraine type, n (%)

Episodic

31,480 (47.28)

347 (32.31)

11,838 (67.20)

3,958 (62.84)

11,087 (64.38)

4,250 (17.44)

Chronic

35,096 (52.72)

727 (67.69)

5,779 (32.80)

2,341 (37.16)

6,134 (35.62)

20,115 (82.56)

Presence of select comorbidities, n (%) a

0

13,961 (20.97)

188 (17.50)

3,860 (21.91)

1,380 (21.91)

3,563 (20.69)

4,970 (20.40)

1

14,946 (22.45)

210 (19.55)

4,017 (22.80)

1,498 (23.78)

3,890 (22.59)

5,331 (21.88)

2

13,080 (19.65)

210 (19.55)

3,470 (19.70)

1,228 (19.50)

3,401 (19.75)

4,771 (19.58)

 ≥ 3

24,589 (36.93)

466 (43.39)

6,270 (35.59)

2,193 (34.82)

6,367 (36.97)

9,293 (38.14)

Prescriber specialty, n (%)

Other

14,661 (22.02)

376 (35.01)

2,842 (16.13)

1,020 (16.19)

2,764 (16.05)

7,659 (31.43)

Home Health

2,299 (3.45)

85 (7.91)

262 (1.49)

130 (2.06)

295 (1.71)

1,527 (6.27)

ER

132 (0.20)

0 (0.00)

47 (0.27)

18 (0.29)

51 (0.30)

16 (0.07)

GP/FP/Internist

9,851 (14.80)

47 (4.38)

3,728 (21.16)

1,018 (16.16)

3,640 (21.14)

1,418 (5.82)

Hospitalist

3,074 (4.62)

192 (17.88)

851 (4.83)

273 (4.33)

774 (4.49)

984 (4.04)

Neurologist

28,954 (43.49)

250 (23.28)

7,519 (42.68)

3021 (47.96)

7,211 (41.87)

10,953 (44.95)

NP/PA

7,541 (11.33)

124 (11.55)

2,357 (13.38)

810 (12.86)

2,455 (14.26)

1,795 (7.37)

Urgent Care

64 (0.10)

0 (0.00)

11 (0.06)

9 (0.14)

31 (0.18)

13 (0.05)

History of oral non–anti-CGRP preventive therapy lines used, n (%) b

0

22,390 (33.63)

252 (23.46)

5,944 (33.74)

2,085 (33.10)

5,634 (32.72)

8,475 (34.78)

1

19,486 (29.27)

256 (23.84)

5,347 (30.35)

1,905 (30.24)

5,271 (30.61)

6,707 (27.53)

2

13,033 (19.58)

233 (21.69)

3,421 (19.42)

1,254 (19.91)

3,435 (19.95)

4,690 (19.25)

 ≥ 3

11,667 (17.52)

333 (31.01)

2,905 (16.49)

1,055 (16.75)

2,881 (16.73)

4,493 (18.44)

History of acute therapy lines used, n (%) c

0

23,384 (35.12)

286 (26.63)

6,047 (34.32)

2,129 (33.80)

5,762 (33.46)

9,160 (37.59)

1

20,653 (31.02)

283 (26.35)

5,849 (33.20)

2,062 (32.74)

5,607 (32.56)

6,852 (28.12)

2

11,348 (17.05)

182 (16.95)

3,002 (17.04)

1,080 (17.15)

3,108 (18.05)

3,976 (16.32)

 ≥ 3

11,191 (16.81)

323 (30.07)

2,719 (15.43)

1,028 (16.32)

2,744 (15.93)

4,377 (17.96)

Use of acute gepant, n (%) d

No

54,986 (82.59)

633 (58.94)

14,922 (84.70)

4,899 (77.77)

14,276 (82.90)

20,256 (83.14)

Yes

11,590 (17.41)

441 (41.06)

2,695 (15.30)

1,400 (22.23)

2,945 (17.10)

4,109 (16.86)

History of emergency department visits, median (Q1, Q3)

 

0 (0, 0)

0 (0, 1)

0 (0, 0)

0 (0, 0)

0 (0, 0)

0 (0, 0)

History of urgent care visits, median (Q1, Q3)

 

0 (0, 0)

0 (0, 0)

0 (0, 0)

0 (0, 0)

0 (0, 0)

0 (0, 0)

History of inpatient hospitalizations, median (Q1, Q3)

 

0 (0, 0)

0 (0, 0)

0 (0, 0)

0 (0, 0)

0 (0, 0)

0 (0, 0)

Charlson comorbidity index, median (Q1, Q3)

 

0 (0, 0)

0 (0, 0)

0 (0, 0)

0 (0, 0)

0 (0, 0)

0 (0, 0)

Copay ($ total patient paid), median (Q1, Q3)

 

40 (0, 122)

0 (0, 312)

40 (9, 80)

45 (0, 122)

40 (0, 85)

0 (0, 225)

# of episodes before index episode, median (Q1, Q3)

 

1 (0, 3)

3 (2, 5)

1 (0, 3)

1 (0, 3)

1 (0, 2)

2 (1, 4)

  1. aComorbidities included: Depression, anxiety, sleep disorders, fibromyalgia, malaise/fatigue, hypertension, ischemic heart disease, cerebrovascular disease, overweight/obesity, and constipation
  2. bAnticonvulsants, antidepressants (SNRIs, TCAs, SSRIs, MAOIs), antihistamines, antihypertensives (ACE inhibitors, ARBs, alpha agonists, beta blockers, calcium channel blockers), NMDA antagonists
  3. cAcute therapy lines use: Triptans, analgesics (narcotic, non-narcotic, anti-inflammatory), hypnotics, ergots, ditans, isometheptene, and antiemetics
  4. dAcute gepant lines include: Rimegepant (may be used acutely or for prevention) and ubrogepant
  5. ACE Angiotensin-converting enzyme, Anti-CGRP Anti-calcitonin gene-related peptide, ARBs Angiotensin II receptor blockers, ER Emergency room, FP Family practitioner, GP General practitioner, HMO Health maintenance organization, MAOIs Monoamine oxidase inhibitors, NMDA N-methyl D-aspartate, NP, Nurse practitioner, PA Physician assistant, PPO Preferred provider organization, SNRI Serotonin and norepinephrine reuptake inhibitors, SSRI Selective serotonin reuptake inhibitors, TCA Tricyclic antidepressants
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us